Following a novel synthetic strategy where the strong uniaxial ligand field generated by the Ph3SiO− (Ph3SiO−=anion of triphenylsilanol) and the 2,4‐di‐tBu‐PhO− (2,4‐di‐tBu‐PhO−=anion of 2,4‐di‐tertbutylphenol) ligands combined with the weak equatorial field of the ligand LN6, leads to [DyIII(LN6)(2,4‐di‐tBu‐PhO)2](PF6) (1), [DyIII(LN6)(Ph3SiO)2](PF6) (2) and [DyIII(LN6)(Ph3SiO)2](BPh4) (3) hexagonal bipyramidal dysprosium(III) single‐molecule magnets (SMMs) with high anisotropy barriers of Ueff=973 K for 1, Ueff=1080 K for 2 and Ueff=1124 K for 3 under zero applied dc field. Ab initio calculations predict that the dominant magnetization reversal barrier of these complexes expands up to the 3rd Kramers doublet, thus revealing for the first time the exceptional uniaxial magnetic anisotropy that even the six equatorial donor atoms fail to negate, opening up the possibility to other higher‐order symmetry SMMs.
Three dysprosium(III) single-molecule magnets (SMMs) with the rare hexagonal bipyramidal geometry have been isolated for the first time. Following a novel synthetic strategy where the strong uniaxial ligand field generated by the Ph<sub>3</sub>SiO<sup>-</sup> (Ph<sub>3</sub>SiO<sup>-</sup> = anion of triphenylsilanol) and the 2,4-di-<sup>t</sup>Bu-PhO<sup>-</sup> (2,4-di-<sup>t</sup>Bu-PhO<sup>-</sup> = anion of 2,4-di-tertbutylphenol) ligands combined with the weak equatorial field of the ligand L<sup>N6</sup>, leads to [Dy<sup>III</sup>(L<sup>N6</sup>)(2,4-di-<sup>t</sup>Bu-PhO)<sub>2</sub>](PF<sub>6</sub>) (<b>1</b>), [Dy<sup>III</sup>(L<sup>N6</sup>)(Ph<sub>3</sub>SiO)<sub>2</sub>](PF<sub>6</sub>) (<b>2</b>) and [Dy<sup>III</sup>(L<sup>N6</sup>)(Ph<sub>3</sub>SiO)<sub>2</sub>](BPh<sub>4</sub>) (<b>3</b>) hexagonal bipyramidal complexes with high anisotropy barriers of U<sub>eff</sub> = 973 K for <b>1</b>, U<sub>eff</sub> = 1080 K for <b>2</b> and U<sub>eff</sub> = 1124 K for <b>3 </b>under zero applied dc field. <i>Ab initio</i> calculations predict that the dominant magnetization reversal barrier of these complexes expands up to the 3rd Kramers doublet, thus revealing for the first time the exceptional uniaxial magnetic anisotropy that even the six equatorial donor atoms fail to negate, opening up the possibility to other higher-order symmetry SMMs. <br>
A combined synthetic, structural, magnetic and computational study gives insight into improving the single-molecule magnet behaviour of stable high-coordinate Dy(iii) complexes.
Following a novel synthetic strategy where the strong uniaxial ligand field generated by the Ph3SiO− (Ph3SiO−=anion of triphenylsilanol) and the 2,4‐di‐tBu‐PhO− (2,4‐di‐tBu‐PhO−=anion of 2,4‐di‐tertbutylphenol) ligands combined with the weak equatorial field of the ligand LN6, leads to [DyIII(LN6)(2,4‐di‐tBu‐PhO)2](PF6) (1), [DyIII(LN6)(Ph3SiO)2](PF6) (2) and [DyIII(LN6)(Ph3SiO)2](BPh4) (3) hexagonal bipyramidal dysprosium(III) single‐molecule magnets (SMMs) with high anisotropy barriers of Ueff=973 K for 1, Ueff=1080 K for 2 and Ueff=1124 K for 3 under zero applied dc field. Ab initio calculations predict that the dominant magnetization reversal barrier of these complexes expands up to the 3rd Kramers doublet, thus revealing for the first time the exceptional uniaxial magnetic anisotropy that even the six equatorial donor atoms fail to negate, opening up the possibility to other higher‐order symmetry SMMs.
The recently reported
compound [Dy
III
LF](CF
3
SO
3
)
2
·H
2
O (L = 1,4,7,10-tetrakis(2-pyridylmethyl)-1,4,7,10-tetraaza-cyclododecane)
displays a strong axial magnetic anisotropy, due to the short axial
Dy–F bond, and single-molecule magnet (SMM) behavior. Following
our earlier [Dy
III
LF]
2+
work, herein we report
the systematic structural and magnetic study of a family of [Ln
III
LF](CF
3
SO
3
)
2
·H
2
O compounds (Ln(III) =
1
-Ce,
2
-Pr,
3
-Nd,
4
-Eu,
5
-Tb,
6
-Ho,
7
-Er,
8
-Tm, and
9
-Yb).
From this series, the Ce(III) and Nd(III) analogues show slow relaxation
of the magnetization under an applied direct current magnetic field,
which is modeled using a Raman process. Complete active space self-consistent
field theoretical calculations are employed to understand the relaxation
pathways in
1
-Ce and
3
-Nd and also reveal
a large tunnel splitting for
5
-Tb. Additional computational
studies on model compounds where we remove the axial F
–
ligand, or replace F
–
with I
–
, highlight the importance of the F
–
ligand in
creating a strong axial crystal field for
1
-Ce and
3
-Nd and for promoting the SMM behavior. Importantly, this
systematic study provides insight into the magnetic properties of
these lighter lanthanide ions.
Following a novel synthetic strategy where the strong uniaxial ligand field generated by the Ph3SiO− (Ph3SiO−=anion of triphenylsilanol) and the 2,4‐di‐tBu‐PhO− (2,4‐di‐tBu‐PhO−=anion of 2,4‐di‐tertbutylphenol) ligands combined with the weak equatorial field of the ligand LN6, leads to [DyIII(LN6)(2,4‐di‐tBu‐PhO)2](PF6) (1), [DyIII(LN6)(Ph3SiO)2](PF6) (2) and [DyIII(LN6)(Ph3SiO)2](BPh4) (3) hexagonal bipyramidal dysprosium(III) single‐molecule magnets (SMMs) with high anisotropy barriers of Ueff=973 K for 1, Ueff=1080 K for 2 and Ueff=1124 K for 3 under zero applied dc field. Ab initio calculations predict that the dominant magnetization reversal barrier of these complexes expands up to the 3rd Kramers doublet, thus revealing for the first time the exceptional uniaxial magnetic anisotropy that even the six equatorial donor atoms fail to negate, opening up the possibility to other higher‐order symmetry SMMs.
The MeCN solvent-induced transformations of heptanuclear LnIII3CoII2CoIII2+ cationic aggregates, associated with literature unknown Ln(iii)-pivalate-based counter anions, to decanuclear LnIII3CoII3/2CoIII4/5 clusters have been investigated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.